Atezolizumab with or without tiragolumab in unresectable esophageal squamous-cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study
Atezolizumab with or without tiragolumab in unresectable esophageal squamous-cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study. // Annals of Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0923753426014316?dgcid=rss_sd_all
Atezolizumab with or without tiragolumab in unresectable esophageal squamous-cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study. Annals of Oncology. https://www.sciencedirect.com/science/article/pii/S0923753426014316?dgcid=rss_sd_all
“Atezolizumab with or without tiragolumab in unresectable esophageal squamous-cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study.” Annals of Oncology.
@article{article35964,
title = {Atezolizumab with or without tiragolumab in unresectable esophageal squamous-cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study},
journal = {Annals of Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0923753426014316?dgcid=rss_sd_all}
}